Ceftaroline fosamil, the prodrug form of ceftaroline, is a novel broad-spectrum parenteral cephalosporin that exhibits antibacterial activity against typical respiratory pathogens such as Streptococcus pneumoniae, Haemophilus influenzae, Staphylococcus aureus and common Gram-negative pathogens. In particular, ceftaroline has activity against resistant Gram-positive cocci, including penicillin-and multidrug-resistant S. pneumoniae, as well as methicillin-resistant S. aureus. The activity of ceftaroline against these phenotypes is attributed to its ability to bind to modified penicillin-binding proteins with high affinity when compared with other b-lactams. The activity of ceftaroline is not compromised by the ability of H. influenzae to produce b-lactamase. Ceftaroline fosamil was compared with ceftriaxone for safety and efficacy in two randomized, double-blinded, controlled Phase III clinical trials for the treatment of community-acquired pneumonia (CAP). Microbiological assessments at baseline included respiratory specimen cultures, blood cultures, urinary antigen testing and atypical pathogen serology testing. By-subject and by-pathogen microbiological outcomes were assessed in the microbiologically evaluable population at the test-of-cure visit. The favourable microbiological response rates by subject for ceftaroline were 87.0% compared with 81.0% for ceftriaxone. The by-pathogen microbiological response rates of ceftaroline and ceftriaxone were 87.3% and 72.9% for S. pneumoniae, 83.3% and 85.0% for H. influenzae and 76.0% and 70.4% for S. aureus, respectively. Key baseline pathogens such as S. pneumoniae, H. influenzae and methicillin-susceptible S. aureus were susceptible to ceftaroline, with MIC 90 s of 0.03, 0.03 and 0.25 mg/L, respectively, supporting its utility as a promising new agent for treatment of CAP.
Introduction
Community-acquired pneumonia (CAP) continues to be a common and serious illness despite the availability of antibiotics and effective vaccines. CAP and influenza combined is the eighth leading cause of death in the USA and has one of the highest mortality rates among infectious diseases. 1 Streptococcus pneumoniae is the most common pathogen implicated in CAP and increasing multidrug-resistant S. pneumoniae (MDRSP) represents a challenge for existing antibacterial agents. 2 Recent US surveillance studies conducted in 2008 have shown that rates of resistance to erythromycin, clindamycin and co-trimoxazole were 37.1%, 20.3% and 22.5%, respectively, among respiratory isolates of S. pneumoniae. 3 Furthermore, prior to the release of the 13-valent vaccine to the market in February 2010, the widespread use of the 7-valent pneumococcal conjugate vaccine (PCV7) resulted in increased prevalence of non-vaccine serotypes, such as 19A, which are often associated with high-level penicillin resistance and multidrug resistance in S. pneumoniae. 4 Haemophilus influenzae are also frequently identified among patients who require hospitalization for CAP, 5 and the prevalence of b-lactamase-producing H. influenzae was 22% in a recent US survey of isolates collected from respiratory specimens. 3 Approximately 25% of cases of CAP in the USA are caused by Staphylococcus aureus, and S. aureus-mediated CAP is associated with increased mortality. 6 Community-acquired methicillinresistant S. aureus (MRSA) is an emerging pathogen associated with severe, necrotizing pneumonia and influenza-associated pneumonia. 7, 8 Although to a lesser extent, CAP is also caused by enteric Gram-negative bacilli, such as Escherichia coli and Klebsiella pneumoniae. 9, 10 Initial therapy for CAP should provide broad coverage against common causative organisms including existing and emerging resistant phenotypes. Ceftaroline fosamil (hereafter referred to as 'ceftaroline') is the prodrug form of ceftaroline, a novel broadspectrum cephalosporin that demonstrates in vitro activity against typical respiratory pathogens, including resistant Grampositive pathogens such as MDRSP and MRSA, as well as common Gram-negative pathogens such as E. coli, K. pneumoniae and b-lactamase-producing H. influenzae.
3 Ceftaroline was recently approved by the US FDA for the treatment of community-acquired bacterial pneumonia (CABP) 11 -14 as well as acute bacterial skin and skin structure infection (ABSSSI). 15, 16 Ceftaroline was compared with ceftriaxone for safety and efficacy in two Phase III clinical studies of CAP [ceFtarOline Community-acquired pneUmonia trial versuS ceftriaxone (FOCUS) 1 and FOCUS 2; registration numbers: NCT00621504 and NCT00509106], and other articles in this Supplement will review the clinical data from these trials. 11, 12 This article will review the microbiological profile of ceftaroline against contemporary respiratory pathogens, its mode of action against S. pneumoniae and S. aureus, and microbiological outcome data from the two FOCUS studies.
In vitro activity
Ceftaroline is active against many contemporary Gram-positive and Gram-negative bacterial pathogens, as demonstrated in a surveillance study conducted in 2008 of 10 496 clinical isolates from 27 medical centres located across the USA (Table 1) (data on file, Cerexa, Inc. and Jacobs et al. 17 ). Among S. pneumoniae, all isolates were inhibited by ceftaroline at concentrations of ≤0.5 mg/L. In particular, ceftaroline retained consistent activity against MDRSP, including the non-PCV7 vaccine serotype 19A strains (MIC 90 s of 0.25 mg/L) that have become increasingly prevalent in recent years. Although ceftriaxone-resistant S. pneumoniae are relatively rare, there were 20 isolates identified in the 2008 surveillance study with ceftriaxone MICs ≥4 mg/L, and these isolates were susceptible to ceftaroline with MICs ranging from ≤0.008 to 0.5 mg/L and an MIC 90 of 0.5 mg/L. Ceftaroline is active against S. aureus, with MIC 90 s of 0.25 and 1 mg/L for oxacillin-susceptible and oxacillin-resistant isolates, respectively. The activity of ceftaroline against H. influenzae is not compromised by the ability of the organism to produce b-lactamase, with MIC 90 s of 0.03 for b-lactamasepositive and 0.015 mg/L for b-lactamase-negative isolates. In a separate report, ceftaroline was shown to have potent in vitro activity against bacteraemia isolates including penicillinresistant S. pneumoniae (PRSP) and MRSA obtained from patients with CAP requiring hospitalization. 18 Among E. coli and K. pneumoniae, the MIC 90 s for ceftazidime-susceptible [non-extended-spectrum b-lactamase (ESBL)-producing] isolates were 0.5 and 0.25 mg/L, respectively. Ceftaroline is not active against ESBL-producing or AmpC-overexpressing members of the Enterobacteriaceae. Ceftaroline also has no activity against non-fermenting Gram-negative species, including Pseudomonas aeruginosa and Acinetobacter spp.
Mode of action
Ceftaroline and other b-lactams act by inhibiting the transpeptidase activity of cell-wall biosynthetic penicillin-binding protein (PBP) enzymes. However, alterations in PBPs can reduce the affinity of binding of b-lactams, resulting in resistance to these antibiotics. Unlike other b-lactams, ceftaroline has demonstrated activity against both b-lactam-susceptible and b-lactam-resistant organisms, including PRSP and MRSA.
S. pneumoniae
Ceftaroline is highly active against S. pneumoniae, with MICs for penicillin-susceptible (PSSP) isolates typically ,0.12 mg/L. PBP-binding studies with PSSP isolates were performed based on a competition assay using a fluorescent b-lactam, Bocillin FL, and demonstrated that the low MICs of ceftaroline and comparators (ceftriaxone and penicillin G in a study by Moisan et al. 19 with strain R6, and ceftriaxone and cefotaxime in a study by Kosowska-Shick et al. 20 with strain 1076) were each associated with similarly high binding affinities for PBP 1A, 1B, 2X, 2A and 3.
Extensive use of b-lactams has created strong selective pressure resulting in the emergence of pneumococci with higher MICs of both penicillin and the cephalosporins. b-Lactam resistance in S. pneumoniae is primarily mediated by altered PBPs, such as PBP 2X. 21 -23 Ceftaroline retains in vitro activity against highly cefotaxime-resistant isolates of S. pneumoniae collected from the Active Bacterial Core surveillance programme of the CDC as well as laboratory-derived mutants of S. pneumoniae with defined combinations of resistance mutations in PBP 2X, PBP 2B and PBP 1A. 24 Ceftaroline has been shown to exhibit a higher affinity for PBP 2X in penicillin-resistant strains with IC 50 values in competition assays that are typically lower than those observed for other b-lactams.
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S. aureus
Ceftaroline is active against both methicillin-susceptible and methicillin-resistant isolates of S. aureus. PBP-binding studies with methicillin-susceptible strain ATCC 29213 demonstrated similar binding affinities of ceftaroline, ceftriaxone and oxacillin for PBP 1, but showed higher affinity of ceftaroline for PBP 3 compared with ceftriaxone and higher affinity of ceftaroline for PBP 2 Critchley et al.
iii46 compared with oxacillin. 19, 20 The activity of ceftaroline against MRSA is reflective of its particular ability to effectively inhibit the modified PBP 2A. 25 PBP 2A, encoded within the SCCmec element unique to MRSA isolates, has low affinity for most b-lactams. The IC 50 of ceftaroline in a competitive displacement assay with PBP 2A was 0.16 mg/L compared with 408 mg/L for oxacillin; results from the PBP affinity assays correlated well with the observed MICs of these agents. 19 Integrated microbiological outcomes in the FOCUS 1 and 2 studies
The FOCUS 1 and 2 trials were double-blinded, multinational studies, and bacterial isolates were collected from subjects enrolled in 26 countries in Asia, Africa, Eastern Europe, Western Europe, North America and South America. A total of 1153 hospitalized adult patients [modified intent-to-treat efficacy (MITTE) population] with moderate to severe CAP [Pneumonia Outcomes Research Team (PORT) risk class III or IV] received either 600 mg of ceftaroline intravenously (iv) every 12 h or 1 g of ceftriaxone iv every 24 h for 5 -7 days. 11, 12, 14 Both studies were similar in design except that patients in the FOCUS 1 study received two 500 mg doses of oral clarithromycin 12 h apart on day 1 of therapy for initial coverage of infections caused by atypical pathogens.
Microbiological evaluations
Respiratory specimens, which included expectorated sputum, induced sputum and deep tracheal, deep bronchial (e.g. bronchoalveolar lavage) or pleural fluid, were submitted to a local laboratory for Gram's staining, culture and susceptibility testing. Sputum samples were considered appropriate for culture if the Gram's stain revealed ≤10 squamous epithelial cells per lowpower field. Isolates were subsequently shipped to a central laboratory for identification confirmation and antimicrobial susceptibility testing using the CLSI reference broth microdilution method. Blood specimens were drawn for culture at enrolment and repeated upon receipt of a positive culture until sterilization was confirmed. Urine specimens were collected at baseline for Figure 1 . Prevalence of pathogens identified in the ME population in the FOCUS 1 and 2 studies (adapted from Critchley et al.
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). Table 2 . Clinical and microbiological success of ceftaroline and ceftriaxone in adults with CAP for all subjects and subjects with monomicrobial and polymicrobial infections at baseline in the ME population in the integrated FOCUS studies (data on file, Cerexa, Inc. and Critchley et al. 
Microbiological efficacy results
The overall recovery rates of pathogens (typical and atypical combined) in the MITTE population were 41.4% (240/580) for ceftaroline-treated patients and 41.0% (235/573) for ceftriaxone-treated patients. The recovery rates for typical pathogens were 29.3% (170/580) among ceftaroline-treated subjects and 30.5% (175/573) among ceftriaxone-treated subjects. These results were consistent with those observed in other CAP studies. 26 The microbiological modified intent-to-treat efficacy (mMITTE) population included subjects who received at least one dose of study drug who also met the minimum criteria for CAP of PORT risk class III or IV and from whom at least one typical bacterial pathogen was isolated at the baseline visit.
Clinical and microbiological response rates were evaluated in the microbiologically evaluable (ME) population. The ME population consisted of all subjects in the clinically evaluable (CE) and mMITTE populations who had at least one typical bacterial pathogen identified at baseline from an appropriate specimen. Microbiological eradication and presumed eradication were considered to be favourable microbiological responses.
The most commonly isolated pathogens in the ME population were S. pneumoniae, S. aureus, H. influenzae, Haemophilus parainfluenzae, K. pneumoniae and E. coli (Figure 1) . 27 The distribution of pathogens was similar to those described previously for this type of infection. 26, 28 The clinical and microbiological response rates for ceftaroline and ceftriaxone for monomicrobial, polymicrobial (mixed infections) and all infections are shown in Table 2 (data on file, Cerexa, Inc. and Critchley et al. 27 ). The clinical success rate for ceftaroline was 85.1% (131/154) compared with 75.5% (111/147) for ceftriaxone for all subjects. Among subjects with monomicrobial infections, similar response rates were also observed for ceftaroline (85.6%) and ceftriaxone (78.4%).
Microbiological response rates by pathogen in the ME population are shown in Table 3 . 27 Overall, .99% of the clinical and 2.9 2.9 2.9 2.9 2.9 2.9 2.9 2.9 Prevalence (%) Figure 2 . Serotype distribution of 57 baseline isolates of S. pneumoniae (data on file, Cerexa, Inc. and Critchley et al.
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). Serotypes with a single isolate (n ¼ 11) are not shown.
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iii48 microbiological responses were concordant. The favourable microbiological response rates for ceftaroline and ceftriaxone against S. pneumoniae were 87.3% (55/63) and 72.9% (43/59), respectively. 27 Among S. pneumoniae, eight isolates were multidrug resistant to two or more antimicrobial classes, with four isolates identified among the ceftaroline-treated subjects and four The favourable microbiological responses against S. aureus for ceftaroline and ceftriaxone were 76.0% (19/25) and 70.4% (19/27) , respectively (Table 3) . 27 As expected in CAP and in view of the exclusion of MRSA from the study, the isolation of MRSA was rare (N¼ 2 isolates) among the 52 baseline isolates of S. aureus. Both MRSA isolates were from ceftriaxone-treated subjects, with a favourable microbiological response for one of the two subjects.
Among subjects with H. influenzae, the favourable microbiological response rates were 83.3% (15/18) for ceftaroline and 85.0% (17/20) for ceftriaxone, and the microbiological response rates for H. parainfluenzae were 100% (16/16) for ceftaroline and 94.1% (16/17) for ceftriaxone (Table 3) . Among E. coli and K. pneumoniae, the favourable microbiological response rates were 83.3% (10/12) and 100% (13/13), respectively, for ceftaroline and 91.7% (11/12) and 83.3% (10/12), respectively, for ceftriaxone.
Serotype distribution of baseline S. pneumoniae isolates
All baseline isolates of S. pneumoniae were serotyped using the capsular swelling reaction with commercial group-and typespecific antisera (Statens Serum Institut, Copenhagen, Denmark). 27 The serotype distributions for the baseline isolates of S. pneumoniae are shown in Figure 2 (data on file, Cerexa, Inc. and Critchley et al. 27 ). Overall, S. pneumoniae serotypes were diverse, with serotype 3 being the most prevalent (13.2%), followed by serotypes 4 and 5 (both 7.4%) and serotypes 1, 10, 14 and 7F (all 5.9%). Two isolates belonging to serotype 19A were identified, which were from the blood and sputum of one ceftriaxone-treated subject who exhibited a favourable microbiological response. The 19A isolates had a ceftriaxone MIC of 0.12 mg/L and were not multidrug resistant. Table 4 shows the susceptibility of baseline pathogens isolated in the FOCUS studies to ceftaroline and comparator agents. All isolates of S. pneumoniae, including MDRSP (defined as strains resistant to two or more antimicrobial classes of drugs, including penicillin, macrolides, tetracycline, fluoroquinolones, chloramphenicol, trimethoprim/sulfamethoxazole and cephalosporins), were inhibited by ceftaroline at concentrations of ≤0.12 mg/L. The MIC 90 s for S. pneumoniae were 0.03 mg/L of ceftaroline and 0.12 mg/L of ceftriaxone. Resistance to at least 1 of 9 agents tested was observed for 15 of 68 (22%) of the S. pneumoniae isolates and included 7 (10.3%) isolates resistant to trimethoprim/sulfamethoxazole, 5 (7.4%) resistant to azithromycin, 4 (5.9%) resistant to clindamycin and 4 (5.9%) resistant to cefuroxime. Ceftaroline was active against S. aureus, with MICs ranging from 0.12 to 0.5 mg/L and an MIC 90 of 0.25 mg/L compared with an MIC 90 of 4 mg/L of ceftriaxone. H. influenzae and H. parainfluenzae were susceptible to ceftaroline, with MIC 90 s of 0.03 and 0.12 mg/L, respectively. Ceftaroline was active against E. coli and K. pneumoniae clinical isolates, with MIC 90 s of 1.0 and 0.5 mg/L, respectively. Among the E. coli, one isolate was resistant to ceftazidime and was probably an ESBLproducing organism. None of the isolates that were identified as persisters (three for ceftaroline and one for ceftriaxone among the ME population) at the test-of-cure or other subsequent visits developed increased MICs (.2-fold increase in MIC) of ceftaroline.
Antimicrobial susceptibility
Summary
In conclusion, ceftaroline is a broad-spectrum cephalosporin with activity against common typical bacterial pathogens that have been implicated as causative agents of CAP. In the two FOCUS studies, 11, 12 ceftaroline demonstrated favourable clinical and microbiological outcomes against the most frequently encountered typical bacterial pathogens. The increased favourable response rates for ceftaroline when compared with ceftriaxone against S. pneumoniae may be attributed to its enhanced potency in vitro when compared with other b-lactams, in part reflecting the unique ability of ceftaroline to bind to PBPs, including modified PBP 2X, with high affinity. 19, 24 Furthermore, the in vitro activity of ceftaroline against bacterial pathogens isolated from patients enrolled in the FOCUS clinical trials demonstrated a susceptibility profile that supports its utility in the treatment of patients with CAP.
